Moderna Inc. and Pfizer Inc. launched two 30,000-subject trials of Covid-19 vaccines that could clear the way for regulatory approval and widespread use by the end of 2020.

European efforts to secure potential COVID-19 vaccines from Pfizer, Sanofi and Johnson & Johnson are mired in wrangles over price, payment method and potential liability costs, three EU officials told Reuters.

The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.

Early data released from trials of three potential coronavirus vaccines, including a closely watched candidate from Oxford University, increased confidence that a vaccine can train the immune system to recognize and fight Covid-19 without serious side effects.

An experimental coronavirus vaccine being developed by AstraZeneca and the University of Oxford was safe and produced an immune response in early-stage clinical trials, data showed, keeping alive the hope AZD1222 could be in use by the end of 2020.

A Covid-19 vaccine developed by CanSino Biologics and China’s military research unit was shown to be safe and induced immune response in most of the recipients, researchers said.

Companies Face Challenge of Enrolling Patients in COVID-19 Vaccine Studies Published: July 6, 2020 By Mark Terry BioSpace   As of June 29, there were 13 vaccines against COVID-19 in human clinical trials. According to the World Health Organization, as of June 22, there were more than 140 vaccines in development. The furthest ahead are […]

A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators. 

AstraZeneca’s experimental COVID-19 vaccine is probably the world’s leading candidate and most advanced in terms of development, the World Health Organization’s (WHO) chief scientist said.

French drugmaker Sanofi SA expects to get approval for the potential COVID-19 vaccine in development with Britain’s GlaxoSmithKline Plc by the first half of 2021, faster than previously anticipated.